Clinical trials show pembrolizumab active against mucosal melanoma, extends survival in bladder cancer.
Using statistical models, predictions were made for death rates from melanoma in 3 three countries and based on availability of a treatment.
Researchers compared the ability of an artificial-intelligence algorithm to recognize and classify skin cancers with the clinical evaluations of dermatologists.
Induction therapy with intravenous interferon α-2b appeared to be no better than observation alone for the management of patients with intermediate-risk melanoma.
Results of a series of Internet surveys revealed customers' perceptions of harms, benefits, and limitations of genetic information received from direct-to-consumer genetic testing.
Comparison studied the effectiveness of sun protection offered by a beach umbrella alone with that of sunscreen with a high sun protection factor.
Melanoma incidence varies by region, and many states have experienced an increase.
A review of data from three large, prospective studies examined a potential association between alcoholic beverage consumption and risk of melanoma.
Despite the effectiveness of dabrafenib in combination with trametinib for metastatic BRAF-mutant melanoma, many patients experience disease progression that often leads to death. In this data analysis, researcher sought to identify clinical factors associated with long-term response and survival.
Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.
Neurotoxicity is not uncommon in patients with melanoma treated with immune checkpoint inhibitors. In this study, therefore, researchers sought to examine the incidence of neurotoxicity across anti-CTLA-4 and anti-PD-1 antibodies at a single institution.
More melanomas are self-detected by women; men tend to have more melanomas in less visible locations.
A newly developed, evidence-based psychoeducational intervention effectively reduced fear of cancer recurrence and stress in patients at high risk for developing another melanoma.
Treatment with pembrolizumab better maintained health-related quality of life compared with chemotherapy in patients with advanced melanoma refractory to ipilimumab.
Pevonedistat was effective for inhibiting proliferation of melanoma cell lines in vitro, research indicates.
Patients with localized melanoma see their supportive care needs peak at their initial cancer diagnosis and if they experience disease recurrence.
Response rates with PD-1 inhibitors in patients with acral and mucosal melanomas were similar to previously reported rates in patients with cutaneous melanoma.
Variants of the MC1R gene, associated with red hair, pale skin, and freckles, increases the number of genetic mutations related to skin cancer and the level of other gene mutations, further increasing the risk for skin cancer.
Cobimetinib in combination with vemurafenib as a standard first-line approach improves survival in patients with BRAF V600 mutation-positive melanoma, updated results of the coBRIM study.
New report doesn't change Task Force's prior statement on skin cancer screening issued in 2009
Training Primary Care Providers to Screen for Melanoma Increases Diagnoses, With Little Affect on Dermatology Visits or Skin SurgeriesJuly 21, 2016
Training primary care providers (PCP) to detect early melanoma led to increased melanoma diagnoses, but had little impact on skin surgeries or dermatology visits.
The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer CareJuly 15, 2016
[Cancer Informatics] In this research, a microsimulation model framework is used to examine the impact of simultaneously altering curative treatment approaches in different phases of melanoma treatment.
Patients receiving PD-1 or PD-L1 antibodies exhibited papular and nodular eruptions with scale, as well as mucosal lesions with lichenoid features, that were typically manageable with topical steroid treatment.
De novo melanomas, which arise from clinically normal skin with no associated nevus, may be more aggressive than nevus-associated melanomas.
In addition to improving overall survival compared with dacarbazine in patients with advanced melanoma, nivolumab maintains baseline levels of health-related quality of life to ultimately confer long-term quality of survival benefit.
Population-based screening for melanoma performed by primary care providers does not cause substantial harm with respect to skin surgeries and dermatology visits.
PEG-IFN did not improve improve outcomes for patients with melanoma compared with IFN. Furthermore, patients receiving PEG-IFN were more likely to discontinue treatment due to toxicity.
Disease-Free Status Is Achieved by Combining Immunotherapy Treatments in Patient With Metastatic MelanomaJune 17, 2016
A patient with refractory metastatic melanoma was successfully treated with a novel combination of 2 different types of immunotherapy.
Cutaneous melanoma is rare on feet, but often advanced at point of diagnosis.
Pembrolizumab provides benefit over ipilimumab in patients with advanced melanoma, regardless of tumor PD-L1 expression status or number of prior therapies, a study presented at the 2016 ASCO Annual Meeting has shown.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|